170 related articles for article (PubMed ID: 23289671)
1. Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.
Shibata A; McMullen E; Pham A; Belshan M; Sanford B; Zhou Y; Goede M; Date AA; Destache CJ
AIDS Res Hum Retroviruses; 2013 May; 29(5):746-54. PubMed ID: 23289671
[TBL] [Abstract][Full Text] [Related]
2. Combination antiretroviral drugs in PLGA nanoparticle for HIV-1.
Destache CJ; Belgum T; Christensen K; Shibata A; Sharma A; Dash A
BMC Infect Dis; 2009 Dec; 9():198. PubMed ID: 20003214
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
Date AA; Shibata A; Goede M; Sanford B; La Bruzzo K; Belshan M; Destache CJ
Antiviral Res; 2012 Dec; 96(3):430-6. PubMed ID: 23041201
[TBL] [Abstract][Full Text] [Related]
4. Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Röshammar D; Simonsson US; Ekvall H; Flamholc L; Ormaasen V; Vesterbacka J; Wallmark E; Ashton M; Gisslén M
J Pharmacokinet Pharmacodyn; 2011 Dec; 38(6):727-42. PubMed ID: 21964996
[TBL] [Abstract][Full Text] [Related]
5. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
[TBL] [Abstract][Full Text] [Related]
6. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.
Chaowanachan T; Krogstad E; Ball C; Woodrow KA
PLoS One; 2013; 8(4):e61416. PubMed ID: 23630586
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.
Destache CJ; Belgum T; Goede M; Shibata A; Belshan MA
J Antimicrob Chemother; 2010 Oct; 65(10):2183-7. PubMed ID: 20729545
[TBL] [Abstract][Full Text] [Related]
8. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
[TBL] [Abstract][Full Text] [Related]
9. Estradiol Levels Are Altered in Human Immunodeficiency Virus-Infected Pregnant Women Randomized to Efavirenz-Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy.
McDonald CR; Conroy AL; Gamble JL; Papp E; Hawkes M; Olwoch P; Natureeba P; Kamya M; Silverman M; Cohan D; Koss CA; Dorsey G; Kain KC; Serghides L
Clin Infect Dis; 2018 Jan; 66(3):428-436. PubMed ID: 29136115
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization, and safety evaluation of poly(lactide-co-glycolide) nanoparticles for protein delivery into macrophages.
Guedj AS; Kell AJ; Barnes M; Stals S; Gonçalves D; Girard D; Lavigne C
Int J Nanomedicine; 2015; 10():5965-79. PubMed ID: 26445538
[TBL] [Abstract][Full Text] [Related]
11. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
12. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
[TBL] [Abstract][Full Text] [Related]
13. pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.
Zhang T; Sturgis TF; Youan BB
Eur J Pharm Biopharm; 2011 Nov; 79(3):526-36. PubMed ID: 21736940
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.
King JR; Acosta EP; Yogev R; Wiznia A; Kraimer J; Graham B; Carey V; Britto P; Jean-Philippe P; Moye J; Watson D
Pediatr Infect Dis J; 2009 Feb; 28(2):159-61. PubMed ID: 19106779
[TBL] [Abstract][Full Text] [Related]
15. Intensification of antiretroviral therapy through addition of enfuvirtide in naive HIV-1-infected patients with severe immunosuppression does not improve immunological response: results of a randomized multicenter trial (ANRS 130 Apollo).
Joly V; Fagard C; Grondin C; Descamps D; Yazdanpanah Y; Charpentier C; Colin de Verdiere N; Tabuteau S; Raffi F; Cabie A; Chene G; Yeni P;
Antimicrob Agents Chemother; 2013 Feb; 57(2):758-65. PubMed ID: 23165467
[TBL] [Abstract][Full Text] [Related]
16. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.
Ma Q; Vaida F; Wong J; Sanders CA; Kao YT; Croteau D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; Morgello S; Simpson DM; Heaton RK; Grant I; Letendre SL;
J Neurovirol; 2016 Apr; 22(2):170-8. PubMed ID: 26407716
[TBL] [Abstract][Full Text] [Related]
17. A 48-week study of fat molecular alterations in HIV naive patients starting tenofovir/emtricitabine with lopinavir/ritonavir or efavirenz.
Domingo P; Gutierrez Mdel M; Gallego-Escuredo JM; Torres F; Mateo MG; Villarroya J; Lamarca K; Domingo JC; Vidal F; Villarroya F; Giralt M
J Acquir Immune Defic Syndr; 2014 Aug; 66(5):457-65. PubMed ID: 24820106
[TBL] [Abstract][Full Text] [Related]
18. Noncovalent PEG Coating of Nanoparticle Drug Carriers Improves the Local Pharmacokinetics of Rectal Anti-HIV Microbicides.
Nunes R; Araújo F; Barreiros L; Bártolo I; Segundo MA; Taveira N; Sarmento B; das Neves J
ACS Appl Mater Interfaces; 2018 Oct; 10(41):34942-34953. PubMed ID: 30234288
[TBL] [Abstract][Full Text] [Related]
19. Using microfluidic platforms to develop CNS-targeted polymeric nanoparticles for HIV therapy.
Martins C; Araújo F; Gomes MJ; Fernandes C; Nunes R; Li W; Santos HA; Borges F; Sarmento B
Eur J Pharm Biopharm; 2019 May; 138():111-124. PubMed ID: 29397261
[TBL] [Abstract][Full Text] [Related]
20. Effects of individual drug and combination antiretroviral therapy on trophoblast proliferation.
Nzuza S; Hadebe SI; Katz AA; Matjila M
Eur J Obstet Gynecol Reprod Biol; 2024 Jul; 298():66-73. PubMed ID: 38733775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
